Trial · NCT01175902
Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma
NCT01175902, Not applicable, Completed, The Catholic University of Korea; results first posted 2014-12-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma. Trials, record NCT01175902. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01175902
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma
- NCT number
- NCT01175902
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 44 participants, actual
- Lead sponsor
- The Catholic University of Korea
- Conditions
- Normal Tension Glaucoma
- Interventions
- dorzolamide/timolol, latanoprost
- First posted
- 2010-08-05
- Last updated
- 2015-01-08
- Results first posted
- 2014-12-12
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Intraocular Pressure (IOP), Period 1 | 4 weeks | IOP (mean IOP) after 4 weeks of treatment |
| Primary | Intraocular Pressure (IOP), Period 2 | 12 weeks | IOP (mean IOP) after treaemt from week 8 to week 12 |
| Primary | Blood Pressure (BP), Period 1 | 4 weeks | systolic and diastolic BP at 4 weeks after use of eyedrops |
| Primary | Blood Pressure (BP), Period 2 | 12 weeks | systolic and diastolic BP measured after treaemt from week 8 to week 12 |
| Secondary | Ocular Perfusion Pressure (OPP), Period 1 | 4 weeks | OPP was calculated according to the following formula: OPP=(1/3 systolic BP + 2/3 diastolic BP) x 2/3 -IOP, diastolic OPP (DOPP)=diastolic BP-IOP |
| Secondary | OPP, Period 2 | 12 weeks | OPP was calculated according to the following formula: OPP=(1/3 systolic BP + 2/3 diastolic BP) x 2/3 -IOP, diastolic OPP (DOPP)=diastolic BP-IOP OPP after treaemt from week 8 to week 12 |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Intraocular Pressure (IOP), Period 1 | 4 weeks | mmHg | MEAN | |
| PRIMARY | Intraocular Pressure (IOP), Period 2 | 12 weeks | mmHg | MEAN | |
| PRIMARY | Blood Pressure (BP), Period 1 | 4 weeks | mmHg | MEAN | |
| PRIMARY | Blood Pressure (BP), Period 2 | 12 weeks | mmHg | MEAN | |
| SECONDARY | Ocular Perfusion Pressure (OPP), Period 1 | 4 weeks | mmHg | MEAN | |
| SECONDARY | OPP, Period 2 | 12 weeks | mmHg | MEAN |
Source ClinicalTrials.gov
Results by group80
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Intraocular Pressure (IOP), Period 1 | Latanoprost, Period 1 | IOP at 8am | 13.72 | Standard Deviation 2.93 | mmHg |
| Intraocular Pressure (IOP), Period 1 | Dorzolamide/Timolol, Period 1 | IOP at 8am | 13.50 | Standard Deviation 3.09 | mmHg |
| Intraocular Pressure (IOP), Period 1 | Latanoprost, Period 1 | IOP at 10am | 13.27 | Standard Deviation 2.37 | mmHg |
| Intraocular Pressure (IOP), Period 1 | Dorzolamide/Timolol, Period 1 | IOP at 10am | 13.36 | Standard Deviation 2.75 | mmHg |
| Intraocular Pressure (IOP), Period 1 | Latanoprost, Period 1 | IOP at 12pm | 13.54 | Standard Deviation 2.30 | mmHg |
| Intraocular Pressure (IOP), Period 1 | Dorzolamide/Timolol, Period 1 | IOP at 12pm | 12.63 | Standard Deviation 2.98 | mmHg |
| Intraocular Pressure (IOP), Period 1 | Latanoprost, Period 1 | IOP at 16pm | 13.77 | Standard Deviation 2.50 | mmHg |
| Intraocular Pressure (IOP), Period 1 | Dorzolamide/Timolol, Period 1 | IOP at 16pm | 13.77 | Standard Deviation 2.61 | mmHg |
| Intraocular Pressure (IOP), Period 1 | Latanoprost, Period 1 | IOP at 20pm | 13.36 | Standard Deviation 1.89 | mmHg |
| Intraocular Pressure (IOP), Period 1 | Dorzolamide/Timolol, Period 1 | IOP at 20pm | 13.63 | Standard Deviation 2.46 | mmHg |
1 to 10 of 80Source ClinicalTrials.gov
See all 80 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Latanoprost | 22 | |
| Overall Study | STARTED | Dorzolamide/Timolol | 22 | |
| Overall Study | COMPLETED | Latanoprost | 22 | |
| Overall Study | COMPLETED | Dorzolamide/Timolol | 22 | |
| Overall Study | NOT COMPLETED | Latanoprost | 0 | |
| Overall Study | NOT COMPLETED | Dorzolamide/Timolol | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Latanoprost | ||
| Total, all-cause mortality | Dorzolamide/Timolol | ||
| Total, other adverse events | Latanoprost | 0 | 44 |
| Total, other adverse events | Dorzolamide/Timolol | 0 | 44 |
| Total, serious adverse events | Latanoprost | 0 | 44 |
| Total, serious adverse events | Dorzolamide/Timolol | 0 | 44 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 26756747 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Latanoprost vs Dorzolamide/Timolol: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01175902
GET https://conductscience.org/api/trials/v1/NCT01175902/results?page=2